Design and syntheses of melanocortin subtype-4 receptor agonists. Part 2: discovery of the dihydropyridazinone motif

Feroze Ujjainwalla; Daniel Warner; Christine Snedden; Ricky D Grisson; Thomas F Walsh; Matthew J Wyvratt; Rubana N Kalyani; Tanya Macneil; Rui Tang; David H Weinberg; Lex Van der Ploeg; Mark T Goulet

doi:10.1016/j.bmcl.2005.06.033

Design and syntheses of melanocortin subtype-4 receptor agonists. Part 2: discovery of the dihydropyridazinone motif

Bioorg Med Chem Lett. 2005 Sep 15;15(18):4023-8. doi: 10.1016/j.bmcl.2005.06.033.

Authors

Feroze Ujjainwalla¹, Daniel Warner, Christine Snedden, Ricky D Grisson, Thomas F Walsh, Matthew J Wyvratt, Rubana N Kalyani, Tanya Macneil, Rui Tang, David H Weinberg, Lex Van der Ploeg, Mark T Goulet

Affiliation

¹ Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065-0900, USA. [email protected]

PMID: 16005624
DOI: 10.1016/j.bmcl.2005.06.033

Abstract

Optimization of the biological activity of a new class of non-peptidyl, pyridazinone derived human melanocortin subtype-4 receptor agonists is disclosed.

MeSH terms

Drug Design*
Humans
Inhibitory Concentration 50
Molecular Structure
Pyridazines / chemical synthesis
Pyridazines / chemistry*
Pyridazines / pharmacology*
Receptor, Melanocortin, Type 4 / agonists*
Receptor, Melanocortin, Type 4 / metabolism
Structure-Activity Relationship

Substances

MC4R protein, human
Pyridazines
Receptor, Melanocortin, Type 4